Please assess the completion status of the following clinical trial:

Trial Title: First-in-Human Study of an Oral Plasmodium Falciparum Plasma Membrane Protein Inhibitor

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy adult (as certified by comprehensive medical assessment including detailed history and complete physical examination), male or female, aged 18 to 55 years of age (inclusive) at screening~* At least 50 kg in weight and body mass index (BMI) between 18 and 34 kg/m\^2~* Able and willing to provide informed consent and to be available for follow-up for the planned duration of the study~* If female, then not of child bearing potential (i.e. permanently sterilized hysterectomy or bilateral oophorectomy at least 6 months before screening; proper documentation required\] and/or post-menopausal defined as 12 months with no menses without an alternative cause and with an estradiol level of \< 30 pg/mL and follicle-stimulating hormone level of \> 40 IU/L at screening)~* Sexually active males must agree to be abstinent or use condoms for the duration of the study.~* Screening laboratories (hematology, chemistries, venous methemoglobin level specified in schedule of evaluations) within normal institutional range or if outside the range, not clinically significant in the opinion of the investigator.~Inclusion Criteria for Participants in Single-dose Cohort Only::~* Agrees not to receive any vaccination within 7 days prior to Day 0 and through Day 7.~* Agrees not to use nonprescription drugs, including vitamins, antacids, and herbal and dietary supplements within 7 days prior to Day 0 and through Day 7. Acetaminophen may be used at doses of ≤ 1 g/day, and ibuprofen may be used at doses of ≤ 1.2 g/day.~* Agrees not to use nicotine containing products from screening through Day 7.~* Agrees not to consume alcohol for the 24 hours prior to Day 0 and through Day 7.~* Agrees not to eat pomegranate, grapefruit or other citrus fruits or drink their juices within 7 days prior to Day 0 and through Day 7.~* Agrees to limit caffeine to no more than 200 mg on Day 0.~* Agrees not to eat or drink (except water) for 10 hours before the Day 0 visit and have no water for the hour prior to dosing.~Exclusion Criteria:~* Presence of a significant medical or psychiatric condition that in the opinion of the investigator precludes participation in the study.~* Clinically significant abnormalities on physical examination that, in the opinion of the investigator, would preclude entry into the study.~* History of having a significant illness within the 2 weeks prior to screening visit. Participants can screen after illness is resolved for two weeks.~* History of clinically significant electrocardiogram abnormalities or clinically significant abnormalities from the screening electrocardiogram.~* G6PD deficiency~* History of hemolytic anemia or methemoglobinemia~* History of severe drug hypersensitivity including a severe allergic reaction, anaphylaxis or convulsions following any medication, vaccination or infusion.~* History of drug or alcohol abuse in the 12 months prior to screening or evidence at screening visit~* Use of nicotine containing products within 30 days prior to screening~* Positive blood test for HBsAg, HCV, or HIV-1~* Participation in a clinical study of another investigational product within 30 days prior to study enrollment, or planning to begin such participation during the study.~* Employment under the direct supervision of the investigators or study staff.~* Receipt of any vaccination within 7 days of dosing.~* Febrile illness within 48 hours of dosing~* Use of any prescription medication within 14 days prior to study drug administration.~* Use of nonprescription drugs, including vitamins, antacids, and herbal and dietary supplements within 7 days prior to study drug administration. Acetaminophen may be used at doses of ≤ 1 g/day, and ibuprofen may be used at doses of ≤ 1.2 g/day.~* Consumption of pomegranate, grapefruit or other citrus fruits or their juices within 7 days prior to study drug administration.~* Use of nicotine containing products from screening to study drug administration.~* Consumption of alcohol within 24 hours prior to study drug administration.~Inclusion Criteria For participants in multi-dose cohort only:~* Agrees not to receive any vaccination within 7 days prior to Day 1 and through Day 10.~* Agrees not to use nonprescription drugs, including vitamins, antacids, and herbal and dietary supplements within 7 days prior to Day 1 and through Day 10. Acetaminophen may be used at doses of ≤ 1 g/day, and ibuprofen may be used at doses of ≤ 1.2 g/day.~* Agrees not to use nicotine containing products from screening through Day 10.~* Agrees not to consume alcohol for the 24 hours prior to Day 1 and through Day 10.~* Agrees not to eat pomegranate, grapefruit or other citrus fruits or drink their juices within 7 days prior to Day 1 and through Day 10.~* Agrees to limit caffeine to no more than 200 mg on Days 1, 2, and 3.~* Agrees not to eat or drink (except water) for 10 hours before the Days 1, 2, and 3 visits and have no water for the hour prior to dosing on each of those days.~Note: As with the single dose study, sexually active must agree to be abstinent or use condoms for the duration of the study (through the Day 14 visit).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- Treatment Arm (Type: EXPERIMENTAL): Participants will receive SJ733, an investigational drug developed at St. Jude Children's Research Hospital, and cobicistat.

Based on this trial design, predict the completion outcome and termination type (if applicable).